Immunotherapy for Fungal Infections
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Opportunistic fungal infections are major causes of morbidity and mortality among immunocompromised individuals. Fungi have evolved complex and coordinated mechanisms to survive in the environment and in the mammalian host. Fungi must adapt to "stressors" in the host (including scarcity of nutrients, pH, and reactive oxygen and nitrogen intermediates) in addition to evading host immunity. Knowledge of the immunopathogenesis of fungal infections has paved the way to promising strategies for immunotherapy. These include strategies that increase phagocyte number, activate innate host defense pathways in phagocytes and dendritic cells, and stimulate antigen-specific immunity (e.g., vaccines). Immunotherapy must be tailored to specific immunocompromised states. Challenges exist in bringing promising immunotherapies from the laboratory to clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic Granulomatous Disease: Report on a National Registry of 368 Patients
Winkelstein, J. A., Marino, M. C., Johnston, R. B., Boyle, J., Curnutte, J., Gallin, J. I., Malech, H. L., Holland, S. M., Ochs, H., Quie, P., et al. (2000) · Medicine · doi:10.1097/00005792-200005000-00003 · Cited by 1,728
Self-citationRoles of heat-shock proteins in innate and adaptive immunity.
Srivastava, P. (2002) · Nature reviews. Immunology · doi:10.1038/nri749 · Cited by 1,069 · cited 1×
“proteins that have been exploited as vaccine adjuvants in cancer and infectious diseases [73-79].”
BackgroundStevens, D. A., Moss, R. B., Kurup, V. P., Knutsen, A. P., Greenberger, P., Judson, M. A., Denning, D. W., Crameri, R., Brody, A. S., Light, M., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376525 · Cited by 790
Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response
Garlanda, C., Hirsch, E., Bozza, S., Salustri, A., De Acetis, M., Nota, R., Maccagno, A., Riva, F., Bottazzi, B., Peri, G., et al. (2002) · Nature · doi:10.1038/nature01195 · Cited by 669
Self-citationTrends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997
McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D., & Warnock, D. W. (2001) · Clinical Infectious Diseases · doi:10.1086/322606 · Cited by 657
Casadevall, A., Cleare, W., Feldmesser, M., Glatman-Freedman, A., Goldman, D. L., Kozel, T. R., Lendvai, N., Mukherjee, J., Pirofski, L.-A., Rivera, J., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.6.1437 · Cited by 298
Price, T. H., Bowden, R. A., Boeckh, M., Bux, J., Nelson, K., Liles, W. C., & Dale, D. C. (2000) · Blood · doi:10.1182/blood.v95.11.3302 · Cited by 253
Dromer, F., Charreire, J., Contrepois, A., Carbon, C., & Yeni, P. (1987) · Infection and Immunity · doi:10.1128/iai.55.3.749-752.1987 · Cited by 243
T Cell Vaccination in Mice with Invasive Pulmonary Aspergillosis
Cenci, E., Mencacci, A., Bacci, A., Bistoni, F., Kurup, V. P., & Romani, L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.1.381 · Cited by 223
Self-citationCoccidioidomycosis: host response and vaccine development
Cox, R. A., & Magee, D. M. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.4.804-839.2004 · Cited by 205
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Segal, B. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0808853 · Cited by 661
Self-citationInvasive Fungal Pathogens: Current Epidemiological Trends
Pfaller, M. A., Pappas, P. G., & Wingard, J. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504490 · Cited by 448
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Nosocomial Fungal Infections: Epidemiology, Infection Control, and Prevention
Alangaden, G. J. (2011) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.11.003 · Cited by 337
Chang, K. C., Burnham, C.-A., Compton, S. M., Rasche, D. P., Mazuski, R., SMcDonough, J., Unsinger, J., Korman, A. J., Green, J. M., & Hotchkiss, R. S. (2013) · Critical Care · doi:10.1186/cc12711 · Cited by 281
Mousset, S., Buchheidt, D., Heinz, W., Ruhnke, M., Cornely, O. A., Egerer, G., Krüger, W., Link, H., Neumann, S., Ostermann, H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-013-1867-1 · Cited by 255
Host-Dependent Patterns of Tissue Injury in Invasive Pulmonary Aspergillosis
Stergiopoulou, T., Meletiadis, J., Roilides, E., Kleiner, D. E., Schaufele, R., Roden, M., Harrington, S., Dad, L., Segal, B., & Walsh, T. J. (2007) · American Journal of Clinical Pathology · doi:10.1309/ujrv9dlc11rm3g8r · Cited by 152
Self-citationBouzani, M., Ok, M., McCormick, A., Ebel, F., Kurzai, O., Morton, C. O., Einsele, H., & Loeffler, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003593 · Cited by 127
“fumigatus properties, via an increase in the antifungal activity of innate immune effector cells (26, 27).”
BackgroundIto, J. I., Lyons, J. M., Hong, T. B., Tamae, D., Liu, Y.-K., Wilczynski, S. P., & Kalkum, M. (2006) · Infection and Immunity · doi:10.1128/iai.00815-06 · Cited by 92
Shepardson, K. M., Jhingran, A., Caffrey, A., Obar, J. J., Suratt, B. T., Berwin, B. L., Hohl, T. M., & Cramer, R. A. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004378 · Cited by 79
“improvement is focused on identification of new antifungal drug targets and compounds, a complementary and important area of investigation is discovering therapies that improve host defense in immunocompromised patients [6].”
Metadata
- Authors
- Segal, B. H., Kwon-Chung, J., Walsh, T. J., Klein, B. S., Battiwalla, M., Almyroudis, N. G., Holland, S. M., & Romani, L.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-02-15
- Volume
- 42
- Issue
- 4
- Pages
- 507-515
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2136633708
- Cited by
- 109
- References
- 13
- FWCI
- 7.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.